Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma.
The occurrence of neuro-endocrine deficiencies following craniospinal irradiation for medulloblastoma is well known, but data concerning the spectrum and prevalence of endocrine abnormalities in adulthood are scarce. We studied endocrine function in 20 (median age 25 years) adult subjects, 8-25 years (median 16 years) after therapy. The radiation dose to the whole cranium and spinal axis was 35 +/- 2.6 Gray (mean +/- standard deviation) with a boost to the posterior fossa of 18 +/- 3.7 Gray. 13 subjects had received additional chemotherapy. In 15 of 20 (75%) subjects, endocrine abnormalities were observed. In 14 (70%), growth hormone (GH) secretion was impaired; 7 (35%) subjects had an absolute GH deficiency, while 7 (35%) showed subnormal responses to insulin-induced hypoglycaemia. In contrast, only 20% (4) of these subjects showed impairment of the hypothalamus-pituitary-thyroid (HPT) axis, while 15% (3) showed central impairment of hypothalamus-pituitary-gonadal (HPG) function. Central impairment of the HPG axis was associated with impaired GH secretion in all cases. Central adrenal insufficiency was not observed. Basal levels of prolactin were normal in all subjects. Young age at treatment was a determinant of GH deficiency in adulthood (P = 0.014). Neither post-treatment interval, nor the use of chemotherapy were determinants of central endocrine impairment in adulthood. In long-term survivors of medulloblastoma, GH deficiency has a high prevalence. In contrast, impairment of the HPG and HPT axis is less common, while central adrenal insufficiency was not observed.
Heikens
J
J
Department of Internal Medicine, Emma Kinderziekenhuis, Amsterdam, The Netherlands.
Michiels
E M
EM
Behrendt
H
H
Endert
E
E
Bakker
P J
PJ
Fliers
E
E
D000293:Adolescent; D000328:Adult; D002528:Cerebellar Neoplasms / Q000150:complications / Q000532:radiotherapy*; D002648:Child; D002675:Child, Preschool; D016371:Cranial Irradiation / Q000009:adverse effects*; D004700:Endocrine System Diseases / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D008527:Medulloblastoma / Q000150:complications / Q000532:radiotherapy*; D010902:Pituitary Gland / Q000378:metabolism; D017741:Survivors; D013961:Thyroid Gland / Q000378:metabolism; D013997:Time Factors
D013006:Growth Hormone